Cargando…
Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study
OBJECTIVES: To estimate the present value of current and future funding needed for HIV treatment and prevention in 9 sub-Saharan African (SSA) countries that account for 70% of HIV burden in Africa under different scenarios of intervention scale-up. To analyse the gaps between current expenditures a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785296/ https://www.ncbi.nlm.nih.gov/pubmed/26948960 http://dx.doi.org/10.1136/bmjopen-2015-009656 |
_version_ | 1782420382377050112 |
---|---|
author | Atun, Rifat Chang, Angela Y Ogbuoji, Osondu Silva, Sachin Resch, Stephen Hontelez, Jan Bärnighausen, Till |
author_facet | Atun, Rifat Chang, Angela Y Ogbuoji, Osondu Silva, Sachin Resch, Stephen Hontelez, Jan Bärnighausen, Till |
author_sort | Atun, Rifat |
collection | PubMed |
description | OBJECTIVES: To estimate the present value of current and future funding needed for HIV treatment and prevention in 9 sub-Saharan African (SSA) countries that account for 70% of HIV burden in Africa under different scenarios of intervention scale-up. To analyse the gaps between current expenditures and funding obligation, and discuss the policy implications of future financing needs. DESIGN: We used the Goals module from Spectrum, and applied the most up-to-date cost and coverage data to provide a range of estimates for future financing obligations. The four different scale-up scenarios vary by treatment initiation threshold and service coverage level. We compared the model projections to current domestic and international financial sources available in selected SSA countries. RESULTS: In the 9 SSA countries, the estimated resources required for HIV prevention and treatment in 2015–2050 range from US$98 billion to maintain current coverage levels for treatment and prevention with eligibility for treatment initiation at CD4 count of <500/mm(3) to US$261 billion if treatment were to be extended to all HIV-positive individuals and prevention scaled up. With the addition of new funding obligations for HIV—which arise implicitly through commitment to achieve higher than current treatment coverage levels—overall financial obligations (sum of debt levels and the present value of the stock of future HIV funding obligations) would rise substantially. CONCLUSIONS: Investing upfront in scale-up of HIV services to achieve high coverage levels will reduce HIV incidence, prevention and future treatment expenditures by realising long-term preventive effects of ART to reduce HIV transmission. Future obligations are too substantial for most SSA countries to be met from domestic sources alone. New sources of funding, in addition to domestic sources, include innovative financing. Debt sustainability for sustained HIV response is an urgent imperative for affected countries and donors. |
format | Online Article Text |
id | pubmed-4785296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47852962016-03-14 Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study Atun, Rifat Chang, Angela Y Ogbuoji, Osondu Silva, Sachin Resch, Stephen Hontelez, Jan Bärnighausen, Till BMJ Open Global Health OBJECTIVES: To estimate the present value of current and future funding needed for HIV treatment and prevention in 9 sub-Saharan African (SSA) countries that account for 70% of HIV burden in Africa under different scenarios of intervention scale-up. To analyse the gaps between current expenditures and funding obligation, and discuss the policy implications of future financing needs. DESIGN: We used the Goals module from Spectrum, and applied the most up-to-date cost and coverage data to provide a range of estimates for future financing obligations. The four different scale-up scenarios vary by treatment initiation threshold and service coverage level. We compared the model projections to current domestic and international financial sources available in selected SSA countries. RESULTS: In the 9 SSA countries, the estimated resources required for HIV prevention and treatment in 2015–2050 range from US$98 billion to maintain current coverage levels for treatment and prevention with eligibility for treatment initiation at CD4 count of <500/mm(3) to US$261 billion if treatment were to be extended to all HIV-positive individuals and prevention scaled up. With the addition of new funding obligations for HIV—which arise implicitly through commitment to achieve higher than current treatment coverage levels—overall financial obligations (sum of debt levels and the present value of the stock of future HIV funding obligations) would rise substantially. CONCLUSIONS: Investing upfront in scale-up of HIV services to achieve high coverage levels will reduce HIV incidence, prevention and future treatment expenditures by realising long-term preventive effects of ART to reduce HIV transmission. Future obligations are too substantial for most SSA countries to be met from domestic sources alone. New sources of funding, in addition to domestic sources, include innovative financing. Debt sustainability for sustained HIV response is an urgent imperative for affected countries and donors. BMJ Publishing Group 2016-03-03 /pmc/articles/PMC4785296/ /pubmed/26948960 http://dx.doi.org/10.1136/bmjopen-2015-009656 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Global Health Atun, Rifat Chang, Angela Y Ogbuoji, Osondu Silva, Sachin Resch, Stephen Hontelez, Jan Bärnighausen, Till Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study |
title | Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study |
title_full | Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study |
title_fullStr | Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study |
title_full_unstemmed | Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study |
title_short | Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study |
title_sort | long-term financing needs for hiv control in sub-saharan africa in 2015–2050: a modelling study |
topic | Global Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785296/ https://www.ncbi.nlm.nih.gov/pubmed/26948960 http://dx.doi.org/10.1136/bmjopen-2015-009656 |
work_keys_str_mv | AT atunrifat longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy AT changangelay longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy AT ogbuojiosondu longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy AT silvasachin longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy AT reschstephen longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy AT hontelezjan longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy AT barnighausentill longtermfinancingneedsforhivcontrolinsubsaharanafricain20152050amodellingstudy |